Ph3 Study of ZL-1310 vs. Investigator's Choice Chemo in 2nd line ES SCLC
Phase III Clinical Trial
A Randomized Open-Label Phase 3 Study of ZL-1310 a DLL3 Antibody-Drug Conjugate (ADC) Compared to Investigator�s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Participating Locations